Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Core Insights - Lantheus Holdings, Inc. reported strong financial results for Q4 and full year 2025, maintaining market leadership with PYLARIFY and expanding its portfolio through acquisitions [2][3][6] Financial Performance - Worldwide revenue for Q4 2025 was $406.8 million, a 4.0% increase from $391.1 million in Q4 2024 [3][7] - GAAP net income for Q4 2025 was $54.1 million, compared to a loss of $11.8 million in Q4 2024, marking a 558.8% improvement [3][7] - Adjusted net income for Q4 2025 was $110.7 million, slightly down by 4.1% from $115.4 million in Q4 2024 [3][7] - Fully diluted earnings per share (EPS) increased to $0.82 in Q4 2025 from a loss of $0.17 in Q4 2024, a 578.8% increase [3][7] Revenue Breakdown - Sales of PYLARIFY decreased by 9.7% to $240.2 million in Q4 2025 [7][21] - DEFINITY sales were $85.3 million, down 1.0% [7][21] - Neuraceq generated $31.0 million in sales, marking a 100% increase as it was newly introduced [7][21] Strategic Focus - The company is sharpening its strategic focus on PET radiodiagnostics and plans to pursue value-maximizing alternatives for its radiotherapeutic assets [2][6][15] - Lantheus aims for up to four FDA approvals in 2026 and is prioritizing execution and investment in its late-stage pipeline [2][6] Guidance for 2026 - The company provided revenue guidance for FY 2026 in the range of $1.4 billion to $1.45 billion and adjusted fully diluted EPS guidance of $5.00 to $5.25 [10]